Silexion Therapeutics Ltd. (SLXN) Stock Score, Valuation & Financial Research

Silexion Therapeutics Ltd. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for SLXN

Silexion Therapeutics Ltd. does not currently have a complete Wall Street Score. The stored market price is USD 0.26. These figures are a research snapshot, not a buy or sell recommendation.

What Silexion Therapeutics Ltd. does

Silexion Therapeutics LTD is a biopharmaceutical company specializing in the discovery and advancement of RNA interference (RNAi)-based cancer therapies and their associated delivery systems, with a focus on treating aggressive solid tumors. The company's strategy for addressing these tumors relies on its proprietary LODER delivery platform. Its product pipeline features several key candidates: SiG12D-LODER, which has progressed through both preclinical studies and an open-label Phase I clinical trial for pancreatic cancer; Prostate-LODER, currently undergoing preclinical evaluation for prostate cancer; and GBM-LODER, also in preclinical development, targeting Glioblastoma Multiforme, a highly malignant primary brain tumor. Founded in 2008, Silexion Therapeutics is headquartered in Jerusalem, Israel.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Silexion Therapeutics Corp is a clinical-stage biotechnology company that does not currently generate revenue from product sales. Its business model focuses on the research and development of RNA interference (RNAi) therapies for the treatment of KRAS-driven cancers, currently operating as a pre-revenue entity reliant on capital raises to fund its clinical trials and operational expenses.

Products and services

  • The company is developing the SIL204-SL Integrated Therapeutic Regimen (SIL204-IR), an RNAi-based therapeutic candidate currently in clinical development for the treatment of locally advanced pancreatic cancer (LAPC).

Business strengths to evaluate

  • Proprietary RNAi technology platform targeting KRAS-driven cancers Source

Business risks and research considerations

  • Clinical-stage development risk and potential failure of clinical trials Source
  • Requirement for significant additional capital to fund future operations and clinical development Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

SLXN financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 0.26
Market capitalization:
110.11K (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -13.96M
Free cash flow:
USD -10.83M
Cash:
USD 2.23M
Total debt:
USD 1.41M
EPS:
USD -56.54

What stands out

  • Free cash flow is USD -10.83M, negative for the stored period.
  • The balance sheet shows USD 2.23M of cash versus USD 1.41M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 819K using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for SLXN

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can SLXN fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is SLXN likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for SLXN to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of SLXN's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research SLXN

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.